Pull to refresh
Logo
Daily Brief
Following Why Sign Up
CBP suspends de minimis exemption for mail shipments, tightening prescription imports

CBP suspends de minimis exemption for mail shipments, tightening prescription imports

Rule Changes

Formal entry rules for FDA-regulated mail take effect October 22; Canadian pharmacies warn of delays and refusals

September 1st, 2026: Canadian pharmacies warn US customers of disruption risk

Overview

Updated Yesterday

Starting October 22, prescription drugs mailed into the United States will require formal customs entry instead of the informal $800-or-less de minimis path. The change comes from a June 24 Customs and Border Protection rule that indefinitely suspends the de minimis exemption for international postal arrivals.

Canadian online pharmacies are warning US customers to expect delays, added scrutiny, and possible refusals. The rule is not an explicit ban on prescription imports, but the new paperwork may make it impractical for foreign pharmacies to keep shipping to American patients.

Why it matters

Americans who order prescription drugs from Canadian pharmacies may lose that option when mail entry rules tighten on October 22.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

$800
De minimis threshold suspended for postal mail
The informal exemption for packages valued at $800 or less no longer applies to international postal arrivals.
$2,500
Ceiling for Entry Type 13 electronic test
CBP's voluntary electronic entry path covers eligible mail shipments valued at $2,500 or less.
2026-10-22
Compliance date for formal entry on regulated mail
Mail shipments subject to another agency's requirements, like FDA-regulated drugs, need formal entry from this date.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

Organizations Involved

U.S. Customs and Border Protection
U.S. Customs and Border Protection
Federal Agency
Rulemaker — issued the June 24 interim final rule

The Department of Homeland Security agency that controls imports entering the United States, including international mail.
U.S. Food and Drug Administration
U.S. Food and Drug Administration
Federal Agency
Admissibility authority for prescription drugs entering the US

The federal agency whose requirements for regulated products trigger formal entry under the new CBP mail rule.
Maple Leaf Medications
Maple Leaf Medications
Canadian Online Pharmacy
Warning US customers of shipment disruption risk

A Canadian online pharmacy that has publicly warned its US customers about the October 22 customs changes.

Timeline

June 2026 October 2026

4 events Latest: September 1st, 2026 · 3 weeks ago
Tap a bar to jump to that date

  1. Compliance date for formal entry on regulated mail

    Upcoming Regulation

    Mail shipments subject to another government agency's requirements, including FDA-regulated prescription drugs, must use formal entry procedures.

  2. Canadian pharmacies warn US customers of disruption risk

    Latest Statement

    Maple Leaf Medications, Your Canada Drug Store, and LifeRx Pharmacy publish notices about potential delays, refusals, and added customs requirements.

  3. Rule's main provisions take effect

    Regulation

    The de minimis suspension applies to mail arrivals; formal entry requirements for regulated mail phase in with an October 22 compliance date.

  4. CBP publishes interim final rule suspending de minimis exemption for postal mail

    Regulation

    The rule suspends the $800 de minimis exemption for international postal arrivals and creates a new postal informal entry process.

Scenarios

1

Canadian pharmacies halt US-bound prescription shipments

Likely Resolves by Jan 31, 2027

Discussed by: Maple Leaf Medications, Your Canada Drug Store, LifeRx Pharmacy — all warn this outcome is possible

If the formal entry process demands information or compliance steps that foreign pharmacies, postal operators, and brokers cannot easily supply, major Canadian mail-order pharmacies stop serving US customers. The pharmacies' own September warnings suggest they expect this path.

2

Entry Type 13 test keeps prescription mail flowing with added friction

Possible Resolves by Q1 2027

Discussed by: CBP's Federal Register notice describing the voluntary electronic entry test

Eligible filers route mail shipments valued at $2,500 or less through the new electronic Entry Type 13 process instead of paper formal entry. Prescription shipments continue but face longer clearance times, added duties, and more FDA scrutiny. The result is disruption, not a halt.

3

FDA enforcement discretion limits the practical impact

Unlikely Resolves by Q1 2027

Discussed by: FDA personal importation guidance; medisearcher.com analysis

FDA continues releasing most personal-use prescription shipments under its enforcement discretion policy, particularly for serious conditions without domestic alternatives. Combined with the Entry Type 13 path, consumers see longer waits but still receive their medications. The legal baseline was already restrictive, so the rule changes process more than outcomes.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

2003–2019

FDA personal importation enforcement discretion (2003–present)

For decades, importing unapproved prescription drugs into the US was technically illegal, but FDA's 2003 guidance (updated 2019) described circumstances where personnel might exercise enforcement discretion — generally personal use of no more than a three-month supply for a serious condition without a domestic alternative.

Then

The gray area let Canadian pharmacy imports flourish as a tolerated practice for US patients.

Now

FDA maintained the position that personal importation of unapproved medicines is generally not permitted and that no automatic right of admission exists.

Why this matters now

The new CBP rule operates on top of this existing legal baseline — FDA admissibility law is unchanged, but the customs-entry environment around it becomes far more structured starting October 22.

February 2025

China-origin de minimis suspension (February 2025)

The US suspended the de minimis exemption for goods arriving from China, ending the duty-free informal entry path that carried hundreds of millions of e-commerce packages from Temu and Shein into the United States.

Then

Shipping timelines lengthened immediately, and customs processing volumes surged as packages moved to formal entry.

Now

The suspension showed how ending de minimis can reshape an import channel's economics within weeks, forcing sellers to relabel, warehouse in the US, or raise prices.

Why this matters now

The October 2026 rule applies the same tool to international postal mail generally — suspending de minimis and shifting packages to formal entry — which is why it can disrupt prescription shipments even without an explicit ban.

Sources

(7)
+1
Federal Register / U.S. Government Publishing Office MediSearcher Maple Leaf Medications Your Canada Drug Store LifeRx Pharmacy WeSearch Federal Register / U.S. Government Publishing Office